Background: The objective of this study is to assess the different of cancer driver gene mutations in lung adenocarcinoma patients with bone metastasis using tilling PCR amplification sequencing (tPAS), a next-generation sequencing (NGS) method, and screen for the driver genes which are associated with bone metastasis of lung cancer. Method: Fifteen clinicopathologic samples from of lung adenocarcinoma combined with bone metastasis patients were collected. Exome sequencing was conducted within 398 tumor-associated genes using CN500 NGS platform. Results: Two hundred and twenty somatic gene mutations were detected, including point mutation, insertion, and deletion. Among all cancer driver genes, the top five gene mutations of EGFR (7/15), TP53 (7/15), ROS1 (3/15), IDH2 (2/15), and SYNE1 (2/ 15) were found to be mutated in lung adenocarcinoma patients; EGFR (7/15), TP53 (5/15), ADGRL3 (2/15), APC (2/15), and KMT2C (2/15) were found to be mutated in bone metastasis patients. Notably, KMT2C gene alternation was only observed in bone metastasis comparing to lung adenocarcinoma patients. In the lung adenocarcinoma mutationnegative cases, tPAS assay identified mutation frequency of EGFR (53.67%), CTNNB1 (16.01%), CASC5 (11.14%), MTOR (5.88%), FH (5.65%), and PIK3C2B (5.56%) in bone metastatic lesions. Moreover, according to over 50% mutation frequencies, the top three genes were EGFR (79.03%), ADGRL3 (75.25%), and FANCD2 (57.81%) in lung adenocarcinoma patients; the top four genes in bone metastasis patients were ADGRL3 (91.28%), EGFR (72.14%), KEAP1 (62.99%), and STK11 (55.18%). In addition, gene mutation frequencies of bone metastasis patients were higher than lung adenocarcinoma patients in EGFR (32.73%, 21.67%, 38.64%, 21.83% VS. 21.80%, 13.14%, 22.69%, 15.11%), KEAP1 (62.99% VS. 20.26%), PBRM1 (25.51% VS. 22.38), PIK3CG (44.74% VS 31.14%), TCF3 (15.00% VS. 12.38%), and TP53 (23.24% VS. 20.72), respectively. There were no significant differences (p>0.05) in correlation of tumor mutation burden (TMB) and lung cancer bone metastasis. TMB may not play a crucial role in bone metastasis. Conclusion: The results indicated that discrepancy of oncogenic mutations between lung adenocarcinoma and bone metastasis may be the biomarkers to predict cancer spreading. The patients with gene mutations found in bone metastases of lung adenocarcinoma suggested new potential molecular targets for diagnostics disease progression monitoring.
Background: Due to the advent of molecular targeted therapy, the therapeutic landscape of advanced NSCLC with certain driver mutations has been changed substantially. Local consolidation therapy with surgery or radiotherapy in combination with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is believed to achieve longer progression-free survival (PFS) for stage IV NSCLC patients with oligometastases. We investigated whether primary tumor resection in non-small cell lung cancer (NSCLC) patients with ipsilateral pleural dissemination could achieve more clinical benefit during first-line targeted therapy. Method: Patients with an initial diagnosis of stage IVa NSCLC who had ipsilateral pleural dissemination and received first-line EGFR-TKIs were included. Overall survival (OS) and progression-free survival (PFS) were analyzed. Median (m)PFS was the primary endpoint. Results: Patients were divided into three groups: 17 cases in the palliative resection (PR) group, 15 in the video-assisted thoracoscopic surgery (VATS) biopsy (VB) group, and 56 in the pneumocentesis (P) group. Median (m)PFS and mOS for the entire cohort were 15.7 and 37.5 months, respectively. MPFS for PR group was 27.4 months, significantly longer than that for the VB and P groups (15.1 months and 13.3 months, respectively (p<0.05)). The mPFS for patients with primary tumors 3.5 cm was 21.4 months, compared with 13.3 months for tumors >3.5 cm (p¼0.017). In PFS multivariate analysis, primary tumor length (HR 1.682) and treatment modality (HR 0.795) were possible independent prognostic factors. The mOS and 5-year OS rate for the PR group was 48.0 months and 44.8%, respectively, compared with 37.5 months and 11.3%, respectively, for patients whose tumors were not resected (p¼0.130). For patients who received subsequent targeted therapy (n¼30) after first progression, mOS and 5-year OS rate were 52.9 months and 48.8%, respectively, compared with 29.6 months and 2.9%, respectively, for patients who received chemotherapy (n¼45) (p¼0.000). In further OS multivariate analysis, subsequent treatment was the only independent prognostic factor (HR 5.873, 95% CI, 2.694e12.804, p¼0.000). Conclusion: Our study demonstrates, for the first time, a role for palliative resection in NSCLC patients with ipsilateral pleural dissemination treated with first-line EGFR-TKIs that results in improved PFS and OS. Subsequent targeted therapy after first progression could achieve a better OS compared with chemotherapy. Background: Lung cancer is very common in malignancies, it is the main cause of cancer death. Lung cancer usually occurs in the elderly, and it is late for diagnosis. However, there are few studies on the prognosis of advanced lung cancer by age groups. The purpose of this study is to investigate the effect of age on the prognosis of advanced lung cancer. Method: We extracted the data of lung cancer patients diagnosed stage IV between 2010 and 2014 from the Surveillance, Epidemiology and End Results (SEER) database in which data of patients with unknown age were excluded. We divided the patients into three groups: younger group (age <50 years old), middle-aged group (age between 50-69 years old) and elder group (age >69 years old). Pearson's c2 test were used to compare the clinical characteristics of patients in different age groups. We identified the factors associated with overall survival (OS) and lung cancer specific survival (LCSS) by Cox regression. Results: Data of total 120,444 patients were collected including 5,156 in younger group, 55,389 in middle-aged group, 59,899 in elder group. For both OS and LCSS, younger patients were better than middle-aged patients, middle-aged patients were better than elder patients. Besides, the LCSS of middle-aged and elderly patients was significantly lower than OS. In addition, male, white, small cell lung cancer, no radiotherapy, poorly differentiated lung cancer were associated with poor prognosis of lung cancer. Conclusion: The prognosis
